Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An early study conducted among those with indolent lymphoma showed promising results.
Study finds that having more diverse gut bacteria was associated with better response to immunotherapy.
The discovery may help explain immunotherapy resistance and hints at new therapies.
Two types of immunotherapy plus chemotherapy shrank tumors in most patients in an early study.
In two large clinical trials, an immune checkpoint inhibitor combined with a targeted therapy had better outcomes than the standard of care.
A third of patients taking neoadjuvant Opdivo for inoperable advanced liver cancer had complete responses in an early analysis.
Atezolizumab plus chemotherapy delays disease progression in people with metastatic triple-negative breast cancer.
Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.
A high-fiber diet may help checkpoint medications work better—but probiotic supplements could interfere with response.
Lung cancer advocate Don Stranathan takes on the No. 1 cancer killer.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.